셀트리온은 인류의 건강과 복지 증진에 기여한다는 사명감
으로, 바이오시밀러 및 바이오신약을 연구·개발·생산하고 있는 대한민국 대표 바이오 기업입니다.
뛰어난 기술력과 혁신적인 아이디어를 바탕으로, 세계최초 항체 바이오시밀러 개발에 성공하여 바이오의약품 시장의 패러다임을 변화시키고 전 세계 바이오시밀러 시장을 선도하고 있습니다.
Celltrion is a leading global biopharmaceutical company that researches, develops,and manufactures antibody biosimilars and new biologics.Since our foundation, we have provided advanced and affordable treatment options for patients for a wide area of diseases, including autoimmune disease. Our launch of the world’s first antibody biosimilar product presented a new paradigm to the global biologics market, and the responsive and efficient development of COVID-19 therapeutics during the current global pandemic has helped people to return back to their everyday lives in full wellness.
We will continue to grow as a global biopharmaceutical company based on our know-how in biotherapeutics and driven business strategy.
Celltrion is Korea's leading biologics company dedic-
ated to research, development, and manufacture of biosimilars and new biopharmaceutical products, with a commitment of contributing to the promotion of human health and social welfare.
Equipped with state-of-the-art technology and a spirit of innovation, we succeeded in developing the world's first mAb biosimilar, bringing about a paradigm shift of the entire biopharmaceutical market, where Celltrion now stands at the forefront.
셀트리온은 인류의 건강과 복지 증진에 기여한다는 사명감
으로, 바이오시밀러 및 바이오신약을 연구·개발·생산하고 있는 대한민국 대표 바이오 기업입니다.
뛰어난 기술력과 혁신적인 아이디어를 바탕으로, 세계최초 항체 바이오시밀러 개발에 성공하여 바이오의약품 시장의 패러다임을 변화시키고 전 세계 바이오시밀러 시장을 선도하고 있습니다.
셀트리온은 인류의 건강과 복지 증진에 기여한다는 사명감으로,
바이오시밀러 및 바이오신약을 연구·개발·생산하고 있는
대한민국 대표 바이오 기업입니다. 뛰어난 기술력과 혁신적인
아이디어를 바탕으로, 세계최초 항체 바이오시밀러 개발에
성공하여 바이오의약품 시장의 패러다임을 변화시키고 전 세계
바이오시밀러 시장을 선도하고 있습니다.
The document discusses the results of a study on the effects of exercise on memory and thinking abilities in older adults. The study found that regular exercise can help reduce the decline in thinking abilities that often occurs with age. Older adults who exercised regularly performed better on cognitive tests and brain scans showed they had greater activity in important areas for memory and learning compared to less active peers.
Celltrion is a South Korean biopharmaceutical company founded in 2002 that develops, manufactures, and markets biosimilar drugs and novel therapeutics. Their goal is to make advanced biologic therapies affordable and accessible to all patients. They have developed the world's first approved biosimilar monoclonal antibodies Remsima (infliximab) and Herzuma (trastuzumab), and have a robust pipeline of additional biosimilar candidates in clinical trials. Beyond biosimilars, Celltrion is also developing novel monoclonal antibodies and other biologics for diseases like influenza, hepatitis B, and cancer.
Celltrion is a South Korean biopharmaceutical company established in 2002 that develops, manufactures, and markets biosimilar drugs (highly similar versions of biologic drugs) with the goal of making advanced therapeutics more affordable and accessible to patients worldwide. Their first biosimilar drugs Remsima (infliximab) and Herzuma (trastuzumab) have been approved in multiple countries. Celltrion has extensive R&D, manufacturing, and clinical trial experience that has enabled the successful development and approval of their biosimilar monoclonal antibody drugs. They have a robust pipeline of additional biosimilar candidates in development.
Celltrion is a leading global biopharmaceutical company that researches, develops,and manufactures antibody biosimilars and new biologics.Since our foundation, we have provided advanced and affordable treatment options for patients for a wide area of diseases, including autoimmune disease. Our launch of the world’s first antibody biosimilar product presented a new paradigm to the global biologics market, and the responsive and efficient development of COVID-19 therapeutics during the current global pandemic has helped people to return back to their everyday lives in full wellness.
We will continue to grow as a global biopharmaceutical company based on our know-how in biotherapeutics and driven business strategy.
Celltrion is Korea's leading biologics company dedic-
ated to research, development, and manufacture of biosimilars and new biopharmaceutical products, with a commitment of contributing to the promotion of human health and social welfare.
Equipped with state-of-the-art technology and a spirit of innovation, we succeeded in developing the world's first mAb biosimilar, bringing about a paradigm shift of the entire biopharmaceutical market, where Celltrion now stands at the forefront.
셀트리온은 인류의 건강과 복지 증진에 기여한다는 사명감
으로, 바이오시밀러 및 바이오신약을 연구·개발·생산하고 있는 대한민국 대표 바이오 기업입니다.
뛰어난 기술력과 혁신적인 아이디어를 바탕으로, 세계최초 항체 바이오시밀러 개발에 성공하여 바이오의약품 시장의 패러다임을 변화시키고 전 세계 바이오시밀러 시장을 선도하고 있습니다.
셀트리온은 인류의 건강과 복지 증진에 기여한다는 사명감으로,
바이오시밀러 및 바이오신약을 연구·개발·생산하고 있는
대한민국 대표 바이오 기업입니다. 뛰어난 기술력과 혁신적인
아이디어를 바탕으로, 세계최초 항체 바이오시밀러 개발에
성공하여 바이오의약품 시장의 패러다임을 변화시키고 전 세계
바이오시밀러 시장을 선도하고 있습니다.
The document discusses the results of a study on the effects of exercise on memory and thinking abilities in older adults. The study found that regular exercise can help reduce the decline in thinking abilities that often occurs with age. Older adults who exercised regularly performed better on cognitive tests and brain scans showed they had greater activity in important areas for memory and learning compared to less active peers.
Celltrion is a South Korean biopharmaceutical company founded in 2002 that develops, manufactures, and markets biosimilar drugs and novel therapeutics. Their goal is to make advanced biologic therapies affordable and accessible to all patients. They have developed the world's first approved biosimilar monoclonal antibodies Remsima (infliximab) and Herzuma (trastuzumab), and have a robust pipeline of additional biosimilar candidates in clinical trials. Beyond biosimilars, Celltrion is also developing novel monoclonal antibodies and other biologics for diseases like influenza, hepatitis B, and cancer.
Celltrion is a South Korean biopharmaceutical company established in 2002 that develops, manufactures, and markets biosimilar drugs (highly similar versions of biologic drugs) with the goal of making advanced therapeutics more affordable and accessible to patients worldwide. Their first biosimilar drugs Remsima (infliximab) and Herzuma (trastuzumab) have been approved in multiple countries. Celltrion has extensive R&D, manufacturing, and clinical trial experience that has enabled the successful development and approval of their biosimilar monoclonal antibody drugs. They have a robust pipeline of additional biosimilar candidates in development.